Antipsychotika haben sich in der medikamentösen Behandlung der Schizophrenie sowohl in der Akutphase als auch in der Langzeitbehandlung als wirksam erwiesen. Mit der Einführung der Antipsychotika der 2. (und 3.) Generation („Atypika”) stehen dem Behandler differenzierte Therapieoptionen hinsichtlich eines günstigeren Nutzen-Risiko-Verhältnisses zur Verfügung. In der vorliegenden Übersicht werden die empfohlenen medikamentösen Behandlungsstrategien in den einzelnen Krankheitsphasen dargelegt und auf der Basis der vorhandenen Evidenz kritisch diskutiert.
Antipsychotics have proven efficacy in the acute phase and long-term pharmacotherapy of schizophrenia. With the introduction of second (and third) generation antipsychotics differential treatment options and an improved risk-benefit ratio become available. In the review the recommended treatment strategies in the different phases of the disease are presented and discussed on the background of evidence-based medicine.
Key words
Schizophrenia - pharmacotherapy - antipsychotics - long-term treatment
Literatur
-
1
Adams CE, Fenton MK, Quraishi S, David AS..
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
Br J Psychiatry.
2001;
179
290-299
-
2
Andreasen NC, Carpenter Jr WT, Kane JM. et al. .
Remission in schizophrenia: proposed criteria and rationale for consensus.
Am J Psychiatry.
2005;
162
441-449
-
3
Baumann P, Hiemke C, Ulrich S. et al. .
The AGNP-TDM expert group consensus guidlines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry.
2004;
37
243-265
-
4
Correll CU, Leucht S, Kane JM..
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Am J Psychiatry.
2004;
161
414-425
-
5 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg.). .S3-Praxisleitlinien Psychiatrie und Psychotherapie. Band 1. Behandlungsleitlinie Schizophrenie. Leitlinienprojektgruppe: Gaebel W, Falkai P, Weinmann S, Wobrock T. Darmstadt: Steinkopff-Verlag 2006
-
6
Falkai P, Wobrock T, Lieberman J. et al. .
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.
World J Biol Psychiatry.
2005;
6
132-191
-
7
Falkai P, Wobrock T, Lieberman J. et al. .
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.
World J Biol Psychiatry.
2006;
7
5-40
-
8
Gaebel W, Riesbeck M, Wölwer W. et al. .
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
J Clin Psychiatry.
2007;
69
1763-1774
-
9
Harvey PD, Keefe RSE..
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
Am J Psychiatry.
2001;
158
176-184
-
10 Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. Heidelberg: Springer-Verlag 1991
-
11
Kohen D..
Diabetes mellitus and schizophrenia: historical perspective.
Br J Psychiatry Suppl.
2004;
184
-
12
Lasser RA, Bossie CA, Gharabawi GM, Kane JM..
Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection.
Schizophr Res.
2005;
77
215-227
-
13
Lehman AF, Lieberman JA, Dixon LB. et al. .
Practice guideline for the treatment of patients with schizophrenia, second edition.
Am J Psychiatry.
2004;
161
1-56
-
14
Leucht S, Barnes TR, Kissling W. et al. .
Relapse pevention in shizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
Am J Psychiatry.
2003;
160
1209-1222
-
15
Loo H, Poirier-Littre MF, Theron M. et al. .
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.
Br J Psychiatry.
1997;
170
18-22
-
16
McGorry P, Killackey E, Elkins K. et al. .
Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia.
Australasian Psychiatry.
2003;
11
136-147
-
17
Mishara AL, Goldberg TE..
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
Biol Psychiatry.
2004;
55
1013-1022
-
18
Möller HJ..
Management of the negative symptoms of schizophrenia. New treatment options.
CNS Drugs.
2003;
17
793-823
-
19
Möller HJ..
Non-neuroleptic approaches to treating negative symptoms in schizophrenia.
Eur Arch Psychiatry Clin Neurosci.
2004;
254
108-116
-
20 National Institute for Clinical Excellence. .Core Interventions in the Treatment of Schizophrenia. NICE, London, 2003. www.nice.org.uk
-
21
Robinson DG, Woerner MG, McMeniman M. et al. .
Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.
Am J Psychiatry.
2004;
161
473-479
-
22
Rummel C, Kissling W, Leucht S..
Antidepressants for the negative symptoms of schizophrenia.
Cochrane Database Syst Rev.
2006;
3
-
23
Schooler N, Rabinowitz J, Davidson M. et al. .
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Am J Psychiatry.
2005;
162
947-953
-
24
Wobrock T, Falkai P..
Leitliniengestützte Therapie schizophrener Psychosen.
INFO Neurologie & Psychiatrie.
2003;
5
34-45
-
25 Wobrock T, Falkai P.. Medikamentöse Langzeittherapie zur Symptomsuppression bei chronisch Schizophrenen. In: Möller HJ (Hrsg.). Therapie psychischer Erkrankungen. Teil II, Behandlung spezieller Erkrankungen, Schizophrene Erkrankungen. 3. vollständig überarbeitete Auflage, Stuttgart: Thieme-Verlag 2006: 274-290
Korrespondenz
Dr. med. Thomas Wobrock
Zentrum für Psycho-soziale Medizin Abteilung für Psychiatrie und Psychotherapie Georg-August-Universität Göttingen
Von-Siebold-Straße 5
37075 Göttingen
